These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 18786842)

  • 21. Canine prostatic carcinoma.
    Axiak SM; Bigio A
    Compend Contin Educ Vet; 2012 Oct; 34(10):E1-5. PubMed ID: 23532757
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Significance of chemoprevention for prostate cancer development: experimental in vivo approaches to chemoprevention.
    Shirai T
    Pathol Int; 2008 Jan; 58(1):1-16. PubMed ID: 18067635
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cancer treatment-induced bone loss in breast and prostate cancer.
    Saad F; Adachi JD; Brown JP; Canning LA; Gelmon KA; Josse RG; Pritchard KI
    J Clin Oncol; 2008 Nov; 26(33):5465-76. PubMed ID: 18955443
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictors of clinical metastasis in prostate cancer patients receiving androgen deprivation therapy: results from CaPSURE.
    Abouassaly R; Paciorek A; Ryan CJ; Carroll PR; Klein EA
    Cancer; 2009 Oct; 115(19):4470-6. PubMed ID: 19637339
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Two new cases of polysomy 13 in canine prostate cancer.
    Reimann-Berg N; Willenbrock S; Murua Escobar H; Eberle N; Gerhauser I; Mischke R; Bullerdiek J; Nolte I
    Cytogenet Genome Res; 2011; 132(1-2):16-21. PubMed ID: 20668368
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Undifferentiated carcinoma in the canine prostate.
    Rabaut SM; Kelch WJ
    Mod Vet Pract; 1979 May; 60(5):401-3. PubMed ID: 470925
    [No Abstract]   [Full Text] [Related]  

  • 27. Clinical and pathologic features of prostatic adenocarcinoma in sexually intact and castrated dogs: 31 cases (1970-1987).
    Bell FW; Klausner JS; Hayden DW; Feeney DA; Johnston SD
    J Am Vet Med Assoc; 1991 Dec; 199(11):1623-30. PubMed ID: 1778750
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Implications of insulin-like growth factor-I for prostate cancer therapies.
    Kojima S; Inahara M; Suzuki H; Ichikawa T; Furuya Y
    Int J Urol; 2009 Feb; 16(2):161-7. PubMed ID: 19183230
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Naturally occurring tumors in dogs as comparative models for cancer therapy research.
    Hahn KA; Bravo L; Adams WH; Frazier DL
    In Vivo; 1994; 8(1):133-43. PubMed ID: 8054503
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bone-targeted therapy: phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer.
    Amato RJ; Hernandez-McClain J; Henary H
    Am J Clin Oncol; 2008 Dec; 31(6):532-8. PubMed ID: 19060583
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel secondary hormonal therapy in advanced prostate cancer: an update.
    Van Allen EM; Ryan CJ
    Curr Opin Urol; 2009 May; 19(3):315-21. PubMed ID: 19342958
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.
    Kintzel PE; Chase SL; Schultz LM; O'Rourke TJ
    Pharmacotherapy; 2008 Dec; 28(12):1511-22. PubMed ID: 19025432
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnostic exercise: epithelioid hemangiosarcoma mimicking metastatic prostatic neoplasia in a dog.
    Shor S; Helfand SC; Gorman E; Löhr CV
    Vet Pathol; 2009 May; 46(3):548-52. PubMed ID: 19176508
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor beta1-associated osteoblastic changes.
    Izumi K; Mizokami A; Li YQ; Narimoto K; Sugimoto K; Kadono Y; Kitagawa Y; Konaka H; Koh E; Keller ET; Namiki M
    Prostate; 2009 Aug; 69(11):1222-34. PubMed ID: 19434660
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Testosterone therapy in men with prostate cancer: scientific and ethical considerations.
    Morgentaler A
    J Urol; 2009 Mar; 181(3):972-9. PubMed ID: 19150547
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pet models in cancer research: general principles.
    Porrello A; Cardelli P; Spugnini EP
    J Exp Clin Cancer Res; 2004 Jun; 23(2):181-93. PubMed ID: 15354401
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A novel model of bone-metastatic prostate cancer in immunocompetent mice.
    Power CA; Pwint H; Chan J; Cho J; Yu Y; Walsh W; Russell PJ
    Prostate; 2009 Nov; 69(15):1613-23. PubMed ID: 19585491
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prostate specific antigen half-time and prostate specific antigen doubling time as predictors of response to androgen deprivation therapy for metastatic prostate cancer.
    Park YH; Hwang IS; Jeong CW; Kim HH; Lee SE; Kwak C
    J Urol; 2009 Jun; 181(6):2520-4; discussion 2525. PubMed ID: 19371894
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Surgical management of common canine prostatic conditions.
    Freitag T; Jerram RM; Walker AM; Warman CG
    Compend Contin Educ Vet; 2007 Nov; 29(11):656-8, 660, 662-3 passim; quiz 673. PubMed ID: 18210976
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [What's new in 2008 in the field of basic and clinical research in prostate cancer?].
    Phé V; Rouprêt M; Salomon L; Soulié M
    Prog Urol; 2009 May; 19 Suppl 2():S29-42. PubMed ID: 19447327
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.